Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIMI bladder-sparing chemoradiotherapy plus nivolumab with or without ipilimumab study
NL-OMON60349Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, ipilimumab, mitomycin c and capecitabine in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Toxicity in phase Ib, Dose-limiting toxicity incidence and 2 more. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NL-OMON60349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60349.